Synthomer (LON:SYNT) Full Year 2024 Results
Key Financial Results
- Revenue: UK£1.99b (up 2.4% from FY 2023).
- Net loss: UK£70.0m (loss narrowed by 33% from FY 2023).
- UK£0.43 loss per share (improved from UK£1.23 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Synthomer EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 21%.
Looking ahead, revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 4.1% decline forecast for the Chemicals industry in the United Kingdom.
Performance of the British Chemicals industry.
The company's shares are up 1.4% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Synthomer (at least 1 which shouldn't be ignored), and understanding them should be part of your investment process.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About LSE:SYNT
Synthomer
Provides specialised polymers and ingredients in the United Kingdom and internationally.
Undervalued with moderate growth potential.
Similar Companies
Market Insights
Community Narratives
